Immunomedics initiated with a Buy at H.C. WainwrightH.C. Wainwright analyst Raghuram Selvaraju started Immunomedics with a Buy rating and $28 price target. IMMU-132 is a pipeline in a single asset, with applicability across a range of solid tumor types known to express trop-2, Selvaraju tells investors in a research note. The analyst believes IMMU-132 would be particularly applicable in second- and third-line triple-negative breast cancer. The drug's efficacy profile should only improve as it migrates towards earlier settings in the treatment continuum, says Selvaraju.Read more at: (source) $IMMUhttps://thefly.com/landingPage... $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or comments.